Cargando…

Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma

BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakai, Masato, Morikawa, Kenichi, Hosoda, Shunichi, Yoshida, Sonoe, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Ohara, Masatsugu, Sho, Takuya, Suda, Goki, Ogawa, Koji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376769/
https://www.ncbi.nlm.nih.gov/pubmed/36158914
http://dx.doi.org/10.4254/wjh.v14.i7.1480
_version_ 1784768205543178240
author Nakai, Masato
Morikawa, Kenichi
Hosoda, Shunichi
Yoshida, Sonoe
Kubo, Akinori
Tokuchi, Yoshimasa
Kitagataya, Takashi
Yamada, Ren
Ohara, Masatsugu
Sho, Takuya
Suda, Goki
Ogawa, Koji
Sakamoto, Naoya
author_facet Nakai, Masato
Morikawa, Kenichi
Hosoda, Shunichi
Yoshida, Sonoe
Kubo, Akinori
Tokuchi, Yoshimasa
Kitagataya, Takashi
Yamada, Ren
Ohara, Masatsugu
Sho, Takuya
Suda, Goki
Ogawa, Koji
Sakamoto, Naoya
author_sort Nakai, Masato
collection PubMed
description BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC. METHODS: In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative. RESULTS: In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; P < 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients. CONCLUSION: In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC.
format Online
Article
Text
id pubmed-9376769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-93767692022-09-23 Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma Nakai, Masato Morikawa, Kenichi Hosoda, Shunichi Yoshida, Sonoe Kubo, Akinori Tokuchi, Yoshimasa Kitagataya, Takashi Yamada, Ren Ohara, Masatsugu Sho, Takuya Suda, Goki Ogawa, Koji Sakamoto, Naoya World J Hepatol Observational Study BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC. METHODS: In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative. RESULTS: In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; P < 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients. CONCLUSION: In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC. Baishideng Publishing Group Inc 2022-07-27 2022-07-27 /pmc/articles/PMC9376769/ /pubmed/36158914 http://dx.doi.org/10.4254/wjh.v14.i7.1480 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Nakai, Masato
Morikawa, Kenichi
Hosoda, Shunichi
Yoshida, Sonoe
Kubo, Akinori
Tokuchi, Yoshimasa
Kitagataya, Takashi
Yamada, Ren
Ohara, Masatsugu
Sho, Takuya
Suda, Goki
Ogawa, Koji
Sakamoto, Naoya
Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
title Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
title_full Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
title_fullStr Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
title_full_unstemmed Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
title_short Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
title_sort pre-sarcopenia and mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376769/
https://www.ncbi.nlm.nih.gov/pubmed/36158914
http://dx.doi.org/10.4254/wjh.v14.i7.1480
work_keys_str_mv AT nakaimasato presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT morikawakenichi presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT hosodashunichi presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT yoshidasonoe presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT kuboakinori presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT tokuchiyoshimasa presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT kitagatayatakashi presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT yamadaren presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT oharamasatsugu presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT shotakuya presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT sudagoki presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT ogawakoji presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma
AT sakamotonaoya presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma